USA flag logo/image

An Official Website of the United States Government

Human Apyrase to Disrupt Cancer Therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88864
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA130192
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Human Apyrase to Disrupt Cancer Therapy
Agency: HHS
Contract: 1R43CA130192-01A2
Award Amount: $196,745.00
 

Abstract:

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, alone or in combination with aspirin, is effective in inhibiting experimental spontaneous metastasis in mice. PUBLI C HEALTH RELEVANCE:Human apyrase represents a highly promising therapy for cancer treatment. We will determine whether the targeted apyrase, alone or in combination with aspirin, is effective in inhibiting experimental metastasis in mice.

Principal Investigator:

Ridong Chen
3146086932
RCHEN@NIDUSCENTER.COM

Business Contact:


rchen@niduscenter.com
Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD SAINT LOUIS, MO 63141

EIN/Tax ID: 431947715
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No